Matched FFPE and ctDNA Analysis using Illumina TruSightTumor 170 NGS Assay

Get in Touch

Our Locations

Matched FFPE and ctDNA Analysis using Illumina TruSightTumor 170 NGS Assay

Technical feasibility for utilizing TruSightTumor 170 NGS assay (+UMIs) to analyze ctDNA

This presentation, given at the BioPharma Innovation Conference in September 2018, highlights Q²Solutions' collaboration with Illumina and an additional pharma partner, where we have demonstrated technical feasibility for utilizing TruSight Tumor 170 Next Generation Sequencing (NGS) assay in the presence of UMIs to enable low frequency mutation detection (down to ~0.4%) in circulating-tumor DNA.

Download this presentation to learn more.

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-SEQ with BioLegend. Describes CITE-seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...